Alopecia areata and the gut-the link opens up for novel therapeutic interventions.

Expert Opin Ther Targets

a Respiratory, Inflammation and Autoimmunity IMED Biotech Unit , AstraZeneca , Gothenburg , Sweden.

Published: June 2018

AI Article Synopsis

  • This review explores how modern society's lifestyle may harm gut integrity, leading to increased intestinal permeability, which could trigger Alopecia Areata (AA) in those genetically predisposed.
  • It discusses the relationship between chronic inflammation, the gut microbiome, and the immune system's responses that may result in inflammation and tissue damage.
  • The authors suggest that addressing gut health and inflammation is crucial for managing AA, advocating for long-term solutions to eliminate the underlying causes rather than just treating symptoms.

Article Abstract

This review aims to raise the potential of the modern society's impact on gut integrity often leading to increased intestinal permeability, as a cause or driver of Alopecia Areata (AA) in genetically susceptible people. With the increasing rate of T cell-driven autoimmunity, we hypothesize that there is a common root cause of these diseases that originates from chronic inflammation, and that the gut is the most commonly exposed area with our modern lifestyle. Areas covered: We will discuss the complexity in the induction of AA and its potential link to increased intestinal permeability. Our main focus will be on the gut microbiome and mechanisms involved in the interplay with the immune system that may lead to local and/or peripheral inflammation and finally, tissue destruction. Expert opinion: We have seen a link between AA and a dysfunctional gastrointestinal system which raised the hypothesis that an underlying intestinal inflammation drives the priming and dysregulation of immune cells that lead to hair follicle destruction. While it is still important to resolve local inflammation and restore the IP around the hair follicles, we believe that the root cause needs to be eradicated by long-term interventions to extinguish the fire driving the disease.

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728222.2018.1481504DOI Listing

Publication Analysis

Top Keywords

alopecia areata
8
increased intestinal
8
intestinal permeability
8
areata gut-the
4
gut-the link
4
link opens
4
opens novel
4
novel therapeutic
4
therapeutic interventions
4
interventions review
4

Similar Publications

Vitiligo: Clinical and Laboratory Characteristics in 573 Saudi Patients.

Clin Cosmet Investig Dermatol

December 2024

Division of Dermatology, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.

Background: Vitiligo is a common disease. Limited studies in Saudi Arabia have explored the detailed clinical characteristics of vitiligo, as outlined in recent consensus reports by vitiligo experts.

Objective: To determine vitiligo prevalence and detailed clinical characteristics in a Saudi cohort.

View Article and Find Full Text PDF

Objective: Alopecia areata (AA) is an autoimmune skin disease. Observational studies have reported an association between AA and cancer. However, the causal relationship between AA and cancer has not been reported.

View Article and Find Full Text PDF

Although genetic, environmental, autoimmune, and psychological factors are believed to play a role in the onset of alopecia areata (AA), the exact cause remains unknown. This study aimed to investigate whether there are differences in traumatic experiences, dissociative symptoms, and alexithymia levels between groups. Fifty eight patients diagnosed with AA, 58 individuals with dermatological diseases thought to have a low psychosomatic component, and 58 individuals not diagnosed with any chronic disease were included in the study.

View Article and Find Full Text PDF

Objectives: To perform a budget impact analysis (BIA) of the adoption of baricitinib for the management of alopecia areata (AA) by a Saudi public sector payer.

Methods: A BIA model was developed to calculate the expected financial impact under two scenarios: the baseline scenario, which reflects the current mix of treatments without baricitinib, and the projected scenario, in which baricitinib is adopted. The model assumed that patients with severe AA and those with mild-to-moderate AA who did not respond to other treatments were eligible for baricitinib treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!